Subtopic Deep Dive

← Traditional and Medicinal Uses of Annonaceae

Acetogenins as Mitochondrial Complex I Inhibitors
Research Guide

What is Acetogenins as Mitochondrial Complex I Inhibitors?

Acetogenins from Annonaceae plants are potent inhibitors of mitochondrial Complex I (NADH-ubiquinone oxidoreductase), disrupting cellular respiration through specific binding.

Annonaceous acetogenins target Complex I with high potency, as demonstrated by Degli Esposti et al. (1994) testing five compounds on mammalian mitochondria (238 citations). McLaughlin (2008) reviews their discovery from paw paw extracts and anti-cancer potential (293 citations). Over 20 papers document their biochemical inhibition kinetics and therapeutic effects.

Curated Papers

Key Challenges

Why It Matters

Acetogenins inhibit energy metabolism, offering leads for cancer therapies; McLaughlin (2008) shows paw paw extracts potent against 3500 screened plants, leading to commercial products. In neurodegeneration, annonacin induces tau pathology in neurons (Escobar-Khondiker et al., 2007, 200 citations) and kills dopaminergic neurons via energy impairment (Lannuzel et al., 2003, 165 citations). Synergistic effects with flavonoids protect against prostate cancer (Yang et al., 2015, 157 citations), linking traditional Annonaceae use to modern pharmacology.

Key Research Challenges

Selectivity Over Other Complexes

Acetogenins potently inhibit Complex I but lack specificity, potentially affecting Complex II or III (Degli Esposti et al., 1994). Structure-activity studies needed to enhance targeting. McLaughlin (2008) notes cytotoxicity limits therapeutic windows.

Neurotoxicity Mechanisms

Annonacin causes tau pathology and dopaminergic neuron death (Escobar-Khondiker et al., 2007; Lannuzel et al., 2003). Dose-response and long-term effects unclear in vivo. Traditional consumption links to Guadeloupe parkinsonism.

Clinical Translation Barriers

Potent in vitro activity (McLaughlin et al., 1998, 699 citations) but poor bioavailability hinders trials. Synergy with flavonoids shown (Yang et al., 2015) requires formulation advances. Scalable isolation from plants challenging.

Essential Papers

The Use of Biological Assays to Evaluate Botanicals

Jerry L. McLaughlin, Lingling L. Rogers, Jon E. Anderson · 1998 · Drug Information Journal · 699 citations

Diastereoselective Allylation of Carbonyl Compounds and Imines: Application to the Synthesis of Natural Products

Miguel Yus, José C. González‐Gómez, Francisco Foubelo · 2013 · Chemical Reviews · 584 citations

We thank the Spanish Ministerio de Ciencia e Innovación (Grant Nos. CTQ2007-65218 and Consolider Ingenio 2010-CSD-2007-00006 and CTQ2011-24165), the Generalitat Valenciana (Grant No. PROMETEO/2009...

Paw Paw and Cancer: Annonaceous Acetogenins from Discovery to Commercial Products

Jerry L. McLaughlin · 2008 · Journal of Natural Products · 293 citations

Extracts of paw paw ( Asimina triloba, Annonaceae) are among the most potent of the 3500 species of higher plants screened for bioactive compounds in our laboratories at Purdue University. The paw ...

Natural substances (acetogenins) from the family <i>Annonaceae</i> are powerful inhibitors of mitochondrial NADH dehydrogenase (Complex I)

Mauro Degli Esposti, Anna Ghelli, Marina Ratta et al. · 1994 · Biochemical Journal · 238 citations

Natural products from the plants of the family Annonaceae, collectively called Annonaceous acetogenins, are very potent inhibitors of the NADH-ubiquinone reductase (Complex I) activity of mammalian...

Cytotoxic and Antiviral Activities of Colombian Medicinal Plant Extracts of the Euphorbia genus

Liliana Betancur‐Galvis, GE Morales, JE Forero et al. · 2002 · Memórias do Instituto Oswaldo Cruz · 205 citations

Forty-seven plant extracts of 10 species of the genus Euphorbia (Euphorbiaceae) used by Colombian traditional healers for the treatment of ulcers, cancers, tumors, warts, and other diseases, were t...

Annonacin, a Natural Mitochondrial Complex I Inhibitor, Causes Tau Pathology in Cultured Neurons

Myriam Escobar-Khondiker, Matthias Höllerhage, Marie‐Paule Muriel et al. · 2007 · Journal of Neuroscience · 200 citations

A neurodegenerative tauopathy endemic to the Caribbean island of Guadeloupe has been associated with the consumption of anonaceous plants that contain acetogenins, potent lipophilic inhibitors of c...

The mitochondrial complex i inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolism

Annie Lannuzel, Patrick P. Michel, Günter U. Höglinger et al. · 2003 · Neuroscience · 165 citations

Reading Guide

Foundational Papers

Start with Degli Esposti et al. (1994) for core inhibition mechanisms (238 citations), then McLaughlin et al. (1998) for assay methods (699 citations), and McLaughlin (2008) for discovery context (293 citations).

Recent Advances

Study Escobar-Khondiker et al. (2007) on tau pathology (200 citations), Lannuzel et al. (2003) on neuron toxicity (165 citations), and Yang et al. (2015) on synergies (157 citations).

Core Methods

Biochemical NADH assays (Degli Esposti et al., 1994); cytotoxicity bioassays (McLaughlin et al., 1998); neuron culture tau assays (Escobar-Khondiker et al., 2007).

How PapersFlow Helps You Research Acetogenins as Mitochondrial Complex I Inhibitors

Discover & Search

Research Agent uses searchPapers('acetogenins Complex I Annonaceae') to find Degli Esposti et al. (1994), then citationGraph reveals McLaughlin (2008) as high-impact forward citation, and findSimilarPapers uncovers Lannuzel et al. (2003) on neurotoxicity.

Analyze & Verify

Analysis Agent applies readPaperContent on Escobar-Khondiker et al. (2007) to extract IC50 values, verifies inhibition claims via verifyResponse (CoVe) against Degli Esposti et al. (1994), and runs PythonAnalysis to plot dose-response curves from extracted data using matplotlib, with GRADE scoring evidence as A-level for mechanistic claims.

Synthesize & Write

Synthesis Agent detects gaps in clinical translation via contradiction flagging between in vitro potency (McLaughlin, 2008) and neurotoxicity (Lannuzel et al., 2003), then Writing Agent uses latexEditText for review drafting, latexSyncCitations for 10+ references, and latexCompile to generate a figure-rich manuscript; exportMermaid visualizes Complex I inhibition pathways.

Use Cases

"Analyze IC50 inhibition kinetics of annonacin from Annonaceae papers using code."

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (NumPy/pandas fits kinetics curves from Degli Esposti et al. 1994 data) → matplotlib plot of dose-response exported as figure.

"Write LaTeX review on acetogenins cancer mechanisms citing McLaughlin."

Synthesis Agent → gap detection → Writing Agent → latexEditText (structure review) → latexSyncCitations (adds McLaughlin 2008, Escobar-Khondiker 2007) → latexCompile → PDF with diagrams.

"Find code for acetogenin synthesis simulations from related papers."

Research Agent → paperExtractUrls (Yus et al. 2013) → paperFindGithubRepo → githubRepoInspect → returns allylation simulation code linked to acetogenin stereochemistry.

Automated Workflows

Deep Research workflow scans 50+ Annonaceae papers via searchPapers → citationGraph → structured report on Complex I inhibition evolution from Degli Esposti (1994) to Yang (2015). DeepScan applies 7-step CoVe analysis to verify annonacin neurotoxicity claims across Lannuzel (2003) and Escobar-Khondiker (2007). Theorizer generates hypotheses on acetogenin-flavonoid synergies for prostate cancer from Yang et al. (2015).

Try Doxa for Acetogenins as Mitochondrial Complex I Inhibitors Research

Frequently Asked Questions

What defines acetogenins as Complex I inhibitors?

Annonaceous acetogenins potently block NADH-ubiquinone reductase; Degli Esposti et al. (1994) measured five compounds' properties on mammalian mitochondria (238 citations).

What methods quantify inhibition?

Biological assays screen botanicals for cytotoxicity (McLaughlin et al., 1998, 699 citations); biochemical assays test NADH dehydrogenase activity (Degli Esposti et al., 1994).

What are key papers?

Foundational: Degli Esposti et al. (1994, 238 citations), McLaughlin (2008, 293 citations); recent: Escobar-Khondiker et al. (2007, 200 citations), Yang et al. (2015, 157 citations).

What open problems exist?

Enhancing selectivity to avoid neurotoxicity (Lannuzel et al., 2003); improving bioavailability for cancer therapy (McLaughlin, 2008); clarifying synergy mechanisms (Yang et al., 2015).